Clinical Trials Logo

Filter by:
NCT ID: NCT05887570 Recruiting - Resident Education Clinical Trials

Procedure-Specific Resident Objective Modular Training Evaluation

PROMOTE
Start date: June 13, 2011
Phase: N/A
Study type: Interventional

Funding for resident training is continually decreasing. The investigators hope to look at innovative ways to improve resident education. The project will investigate whether skills acquired in a surgical lab result in improved operating room (OR) surgical skills. This will be a randomized controlled trial that will split residents up into an intervention group and a control group. The intervention group will be required to pass training modules for six essential surgeries before operating in the OR. In the OR, both groups will be graded by the supervising doctor and be asked to rate themselves using validated questionnaires.

NCT ID: NCT05887102 Recruiting - Breast Cancer Clinical Trials

Pilot Study of PACHA Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors

PACHA
Start date: June 7, 2023
Phase: N/A
Study type: Interventional

The goal of this randomized controlled pilot study is to assess the feasibility, acceptability, and preliminary effects of the PACHA program designed for women having an adjuvant endocrine therapy (AET) after hormone-sensitive breast cancer. PACHA (programme en Pharmacie pour l'ACcompagnement des femmes ayant de l'Hormonothérapie Adjuvante) is a community pharmacy-based program aimed at optimizing the experience of AET and its use. The main questions it aims to answer are : - Does the program have an effect on factors expected to influence AET adherence? - Is the program acceptable? - Is the implementation of the program feasible? - What is the feasibility of procedures for carrying out a full-scale study? Participating community pharmacies will be randomized. Pharmacists working in pharmacies assigned to the PACHA group (33 pharmacies) will receive web-based training and manuals to use during their consultations with women having an AET. Recruited women attending these pharmacies will also have access to information and resources about AET (videos, evidence-based booklet). Pharmacists practicing in pharmacies assigned to the control group (33 pharmacies) will provide usual care.

NCT ID: NCT05885685 Recruiting - Healthy Clinical Trials

Investigating the Effects of Nabilone on Endocannabinoid Metabolism

NABI
Start date: October 31, 2023
Phase: Phase 4
Study type: Interventional

The purpose of this study is to learn about the effects of a cannabis-like substance, nabilone, on the levels of endocannabinoid enzyme fatty acid amide hydrolase (FAAH) in brain of healthy individuals. Using magnetic resonance imagine (MRI) and positron emission tomography (PET), the main questions we aim to answer are: 1) Does nabilone decrease levels of FAAH in the brain? and 2) Are changes in levels of FAAH associated with clinical response to nabilone? Participants will complete: - An in-person interview (~4 hours) - Two brain imaging scanning sessions (~11 hours) - A one week 2 mg titrated dose of nabilone - Virtual check-ins (up to ~1.5 hours)

NCT ID: NCT05884736 Recruiting - Organ Transplant Clinical Trials

Confirming Permanent Lack of Blood Flow to the Brain During A-NRP DCC Organ Transplant

CONCLUDE
Start date: April 2, 2024
Phase:
Study type: Observational

This study aims to evaluate the surgical technique used in Abdominal Normothermic Regional Perfusion (A-NRP) in death determination by circulatory criteria (DCC) organ donors. The proposed study will demonstrate that there is no resumption of brain blood flow or activity during the A-NRP procedure. This will be assessed using multimodal neuromonitoring protocol that enables continuous focused monitoring of brain blood flow and activity during A-NRP. This will provide evidence that brain blood flow and activity does not resume during NRP and ensure donor safety in using this technique in standard of care practice.

NCT ID: NCT05884398 Recruiting - Clinical trials for Metastatic Castrate-sensitive Prostate Cancer

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

LIBERTAS
Start date: August 31, 2023
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level < 0.2 nanograms/millilitres (ng/mL) after 6 months of treatment with apalutamide and ADT combination therapy provides non-inferior radiographic progression-free survival (rPFS) and a reduced burden of hot flashes measured as 18-month percent change in severity adjusted hot flash score.

NCT ID: NCT05884099 Recruiting - Lung Cancer Clinical Trials

Intercostal Cryoanalgesia for Chronic Pain After VATS Lung Resection

CRYO-VATS-2
Start date: November 9, 2023
Phase: N/A
Study type: Interventional

Intercostal cryoanalgesia is a technique that allows extensive and prolonged analgesia of the hemithorax. The aim of this study is to demonstrate the efficacy of intercostal cryoanalgesia as an adjunct to a single-injection paravertebral block for the prevention of chronic thoracic pain after VATS lung resection surgery.

NCT ID: NCT05883358 Recruiting - Withdrawal Syndrome Clinical Trials

Kratom Use Disorder Management Using Clonidine and/or Buprenorphine

Start date: July 2, 2018
Phase:
Study type: Observational

Kratom is used for stimulant, analgesic, anxiolytic, and sedative effects. There is inadequate knowledge about Kratom addiction. Kratom withdrawal may be treated like opioid withdrawal. Prospective observational crossover study of consenting adults who are undergoing Kratom withdrawal management. On alternate weeks, each patient receives treatment using Buprenorphine 5cmg/hr patch; or Clonidine tablet 0.1mg 4hourly; or combined Clonidine tablet 0.1mg 4hourly + Buprenorphine 5cmg/hr patch. Each patient will undergo treatment for 12 weeks. Patients will use Subjective Opiate Withdrawal Scale (SOWS) to collect data on daily basis. SOWS is a patient-administered tool that is used to record the severity and presence of opiate withdrawal. The physician will also use Clinical Opiate Withdrawal Scale (COWS) to collect data on weekly basis. COWS is a clinician-administered tool that is used to record the signs of opiate withdrawal. A change in the COWS and SOWS scores by 6-points is considered significant.

NCT ID: NCT05882877 Recruiting - Atopic Dermatitis Clinical Trials

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

ROCKET-ASCEND
Start date: May 31, 2023
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

NCT ID: NCT05882461 Recruiting - Clinical trials for Acquired Brain Injury

An E-health Letter Intervention for Caregivers

90Second
Start date: February 17, 2021
Phase: N/A
Study type: Interventional

The purpose of the present study is to conduct a two-arm Randomized Control Trial (RCT) comparing individuals receiving the 90Second Caregiver health letter, with a usual care (routine care received by caregivers) control group. The goals of the present study are: - To evaluate the effectiveness of the 90Second Caregiver health letter in improving caregiver's self-efficacy (primary outcome), savouring, and quality of life (secondary outcomes). - To evaluate the effectiveness of the 90Second Caregiver health letter in reducing caregiver's psychological strain and caregiver burden (secondary outcomes). - To examine the impact of levels of engagement with the 90Second Caregiver health letter on primary and secondary outcomes. - To assess the usability of the 90Second Caregiver health letter, as it relates to the relevance of topic, user friendliness, and appropriateness of the readability levels. - To evaluate psychometric properties of self-constructed measures in 90Second newsletter.

NCT ID: NCT05882357 Recruiting - Cystic Fibrosis Clinical Trials

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Start date: June 27, 2023
Phase: Phase 3
Study type: Interventional

This study will evaluate the pharmacokinetics (PK), safety, tolerability, pharmacodynamics (PD), and efficacy of ELX/TEZ/IVA in CF subjects 12 to less than (<) 24 months of age.